Societal CDMO (FRA:RAH) Debt-to-Asset : 0.28 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Societal CDMO Debt-to-Asset?

Societal CDMO's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €34.72 Mil. Societal CDMO's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.12 Mil. Societal CDMO's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €140.74 Mil. Societal CDMO's debt to asset for the quarter that ended in Dec. 2023 was 0.28.

Societal CDMO Debt-to-Asset Historical Data

The historical data trend for Societal CDMO's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Debt-to-Asset Chart

Societal CDMO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

1.00

1.06

0.65

0.28

Societal CDMO Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.28	0.29	0.29	0.28	0.28

Competitive Comparison of Societal CDMO's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Societal CDMO's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Debt-to-Asset falls into.

Societal CDMO Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Societal CDMO's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(34.719	+	4.119)	/	140.736
	=	0.28

Societal CDMO's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(34.719	+	4.119)	/	140.736
	=	0.28

Societal CDMO (FRA:RAH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Societal CDMO Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Societal CDMO (FRA:RAH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (FRA:RAH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SCTL:USA

Address

1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341

Website

https://www.societalcdmo.com

Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Societal CDMO (FRA:RAH) Headlines

No Headlines